RiverPark Advisors LLC Has $795,000 Holdings in Edwards Lifesciences Corporation $EW

RiverPark Advisors LLC lessened its holdings in Edwards Lifesciences Corporation (NYSE:EW) by 49.1% during the 2nd quarter, according to its most recent filing with the Securities and Exchange Commission. The fund owned 10,167 shares of the medical research company’s stock after selling 9,822 shares during the quarter. RiverPark Advisors LLC’s holdings in Edwards Lifesciences were worth $795,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds have also modified their holdings of the company. Rosenberg Matthew Hamilton acquired a new stake in shares of Edwards Lifesciences during the second quarter worth $28,000. Quantbot Technologies LP bought a new stake in shares of Edwards Lifesciences in the 1st quarter valued at about $26,000. NewSquare Capital LLC raised its position in shares of Edwards Lifesciences by 57.8% in the 2nd quarter. NewSquare Capital LLC now owns 366 shares of the medical research company’s stock valued at $29,000 after acquiring an additional 134 shares during the period. SouthState Corp acquired a new position in Edwards Lifesciences during the first quarter valued at approximately $27,000. Finally, Costello Asset Management INC bought a new stake in Edwards Lifesciences in the first quarter valued at approximately $29,000. 79.46% of the stock is owned by institutional investors.

Insider Activity at Edwards Lifesciences

In other Edwards Lifesciences news, VP Daniel J. Lippis sold 1,020 shares of the stock in a transaction on Monday, November 10th. The shares were sold at an average price of $82.55, for a total value of $84,201.00. Following the completion of the sale, the vice president owned 22,002 shares in the company, valued at $1,816,265.10. This trade represents a 4.43% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available through this link. Also, CFO Scott B. Ullem sold 13,000 shares of Edwards Lifesciences stock in a transaction dated Monday, November 10th. The shares were sold at an average price of $83.08, for a total transaction of $1,080,040.00. Following the completion of the transaction, the chief financial officer directly owned 39,898 shares of the company’s stock, valued at approximately $3,314,725.84. This trade represents a 24.58% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Corporate insiders own 1.29% of the company’s stock.

Wall Street Analyst Weigh In

EW has been the subject of several research analyst reports. Oppenheimer lowered shares of Edwards Lifesciences from an “outperform” rating to a “market perform” rating in a report on Wednesday, October 8th. The Goldman Sachs Group set a $104.00 target price on Edwards Lifesciences and gave the company a “buy” rating in a research note on Friday, October 31st. JPMorgan Chase & Co. increased their price target on Edwards Lifesciences from $85.00 to $90.00 and gave the stock a “neutral” rating in a report on Friday, October 31st. Mizuho lifted their price objective on Edwards Lifesciences from $90.00 to $100.00 and gave the company an “outperform” rating in a report on Friday, October 31st. Finally, Stifel Nicolaus increased their target price on Edwards Lifesciences from $85.00 to $95.00 and gave the stock a “buy” rating in a research note on Friday, October 31st. Three research analysts have rated the stock with a Strong Buy rating, fourteen have issued a Buy rating, ten have given a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average target price of $91.39.

Edwards Lifesciences Price Performance

Shares of EW opened at $86.80 on Wednesday. The company has a 50 day moving average of $79.20 and a 200-day moving average of $78.25. The company has a quick ratio of 3.87, a current ratio of 4.68 and a debt-to-equity ratio of 0.06. The stock has a market capitalization of $50.37 billion, a P/E ratio of 12.49, a P/E/G ratio of 3.97 and a beta of 1.03. Edwards Lifesciences Corporation has a twelve month low of $65.94 and a twelve month high of $87.21.

Edwards Lifesciences (NYSE:EW) last issued its quarterly earnings results on Thursday, October 30th. The medical research company reported $0.67 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.59 by $0.08. The firm had revenue of $1.55 billion for the quarter, compared to analyst estimates of $1.49 billion. Edwards Lifesciences had a net margin of 72.96% and a return on equity of 15.01%. The company’s revenue was up 14.7% compared to the same quarter last year. During the same period in the previous year, the business earned $0.67 EPS. Edwards Lifesciences has set its FY 2025 guidance at 2.560-2.620 EPS. Q4 2025 guidance at 0.580-0.640 EPS. As a group, equities research analysts forecast that Edwards Lifesciences Corporation will post 2.45 EPS for the current fiscal year.

Edwards Lifesciences Company Profile

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.